Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data.

JNCI cancer spectrum - 1 Nov 2022

Iyer Pritish, Deng Mengying, Handorf Elizabeth A, Nakhoda Shazia, Dotan Efrat

Abstract excerpt

BACKGROUND: Despite national guideline recommendations for universal biomarker testing (KRAS, NRAS, BRAF, and mismatch repair and microsatellite instability [MMR/MSI]) in all patients with metastatic colorectal cancer (mCRC), little is known regarding adherence to these recommendations in routine practice. METHODS: We retrospectively reviewed patients with mCRC diagnosed between January 1, 2013, and December 27,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Colonic Neoplasms
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Microsatellite Instability

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Rectal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36149298
DOI: 10.1093/jncics/pkac065
PMCID: PMC9664970

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data.PMID 36149298Read ↗

Biomarker Testing Disparities in Metastatic Colorectal CancerSemantic proximity Read ↗

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy.Semantic proximity Read ↗

Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database.Semantic proximity Read ↗

KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Semantic proximity Read ↗

Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.Semantic proximity Read ↗

Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.Semantic proximity Read ↗

KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.Semantic proximity Read ↗

Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.Semantic proximity Read ↗

Racial Differences in Stage IV Colorectal Cancer Molecular Profiling and Mutation Rates.Semantic proximity Read ↗

Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada.Semantic proximity Read ↗

Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.